Bharat Biotech gets rights for nasal covid vaccine tech, eyes 100 crore doses
An intranasal vaccine will not only be simple to administer
It will also reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive
Hyderabad-based Bharat Biotech and US-based biotech firm Precision Virologics have jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Bharat Biotech will own the rights to distribute the nasal covid vaccine, subject to regulatory approvals, in all markets except the US, Japan and Europe.